What is the Return on Assets (ROA) of BioLine RX this year?
The Return on Assets (ROA) of BioLine RX is -0.95 undefined this year.
In 2024, BioLine RX's return on assets (ROA) was -0.95, a 190.28% increase from the -0.33 ROA in the previous year.
BioLine RX's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Comparing BioLine RX's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Investors consider BioLine RX's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Variations in BioLine RX’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
The Return on Assets (ROA) of BioLine RX is -0.95 undefined this year.
The ROA of BioLine RX has increased by 190.28% compared to the previous year.
A high ROA is advantageous for investors of BioLine RX, as it indicates that the company efficiently utilizes its assets and generates good profits.
A low ROA can be unfavorable for investors of BioLine RX as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
An increase in ROA of BioLine RX can be an indicator of improved efficiency in asset utilization and higher profitability.
A reduction in the ROA of BioLine RX can be an indicator of lower asset efficiency and profitability.
Some factors that can influence the ROA of BioLine RX include revenue, operating costs, asset structure, and industry average.
The ROA of BioLine RX is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
To improve ROA, BioLine RX can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
Over the past 12 months, BioLine RX paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BioLine RX is expected to pay a dividend of 0 USD.
The current dividend yield of BioLine RX is .
BioLine RX pays a quarterly dividend. This is distributed in the months of .
BioLine RX paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
BioLine RX is assigned to the 'Health' sector.
To receive the latest dividend of BioLine RX from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.
The last dividend was paid out on 10/1/2024.
In the year 2023, BioLine RX distributed 0 USD as dividends.
The dividends of BioLine RX are distributed in USD.
Our stock analysis for BioLine RX Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioLine RX Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.